Vault-13

CARA THERAPEUTICS INC

COM · CUSIP 140755109

1 institutional holders -69 vs Q3 2024
20,16420.2k shares reported held*
$7.2kreported value*
0 new 0 added 0 reduced 68 sold out net sold ≈ $4.8m (-13.5m shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.35.

Trends to Q4 2024

Institutional holders

Managers reporting a position, each quarter

0100200Q3 22: 165Q4 22: 162Q1 23: 163Q2 23: 137Q3 23: 123Q4 23: 112Q1 24: 102Q2 24: 82Q3 24: 70Q4 24: 11Q3 22Q1 23Q3 23Q1 24Q3 24Q4 24
Numbers
QuarterHolders
Q3 2022165
Q4 2022162
Q1 2023163
Q2 2023137
Q3 2023123
Q4 2023112
Q1 2024102
Q2 202482
Q3 202470
Q4 20241

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
1000100Q1 23: 71 bought or addedQ1 23: 85 cut or sold outQ2 23: 69 bought or addedQ2 23: 84 cut or sold outQ2 23Q3 23: 52 bought or addedQ3 23: 71 cut or sold outQ4 23: 46 bought or addedQ4 23: 61 cut or sold outQ4 23Q1 24: 35 bought or addedQ1 24: 57 cut or sold outQ2 24: 30 bought or addedQ2 24: 62 cut or sold outQ2 24Q3 24: 11 bought or addedQ3 24: 50 cut or sold outQ4 24: 0 bought or addedQ4 24: 68 cut or sold outQ4 24
Numbers
QuarterBought or addedCut or sold out
Q1 20237185
Q2 20236984
Q3 20235271
Q4 20234661
Q1 20243557
Q2 20243062
Q3 20241150
Q4 2024068

Calls vs puts

Options held, notional value, last 4 quarters. P/C = puts ÷ calls

CallsPuts
$0$20k$40k$60kQ1 24 calls: $45.5kQ1 24 puts: $3.5kQ1 24P/C 0.08Q2 24 calls: $15.5kQ2 24 puts: $129Q2 24P/C 0.01Q3 24 calls: $1.6kQ3 24 puts: $0Q3 24P/C 0.00Q4 24 calls: $0Q4 24 puts: $0Q4 24P/C —
Numbers
QuarterCallsPutsP/C
Q1 2024$45.5k$3.5k0.08
Q2 2024$15.5k$1290.01
Q3 2024$1.6k$00.00
Q4 2024$0$0—

Biggest buyers

None

Biggest sellers

VANGUARD GROUP INC Sold out -2,248,911-2.2m
Chescapmanager LLC Sold out -1,702,110-1.7m
FARALLON CAPITAL MANAGEMENT, L.L.C. Sold out -1,556,251-1.6m
DISCIPLINED GROWTH INVESTORS INC /MN Sold out -1,113,043-1.1m
RENAISSANCE TECHNOLOGIES LLC Sold out -1,108,931-1.1m
TWO SIGMA ADVISERS, LP Sold out -866,300-866.3k
BlackRock, Inc. Sold out -742,477-742.5k
MILLENNIUM MANAGEMENT LLC Sold out -587,909-587.9k
BNP PARIBAS FINANCIAL MARKETS Sold out -582,536-582.5k
GEODE CAPITAL MANAGEMENT, LLC Sold out -452,249-452.2k

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Vifor (International) Ltd 13D · may seek influence filed 2024-12-18
Stated purposeThe information set forth in Item 4 is hereby amended and supplemented to read as follows: Asset Purchase Agreement On December 17, 2024, the Issuer and its subsidiary Cara Royalty Sub, LLC ("Royalty Sub" and together with the Issuer, each, a "Seller" and together, the "Sellers") entered into an Asset Purchase Agreement (the "APA") with Vifor Fresenius Medical Care Renal Pharma, Ltd., a majority-owned, indirect subsidiary of CSL Limited ("CSL Vifor"), pursuant to which, at the consummation of the transaction, Sellers will sell to CSL Vifor and CSL Vifor will acquire from Sellers certain assets and rights for the development, manufacture and commercialization of difelikefalin as well as certain associated liabilities (the "Asset Disposition") for a purchase price of $900,000 (subject to … Full filing
13.5% 7.4m 2024-12-18

Holders, Q4 2024

#ManagerLocationShares Value% of their portfolioChangeShares change
1 Rathbones Group PLC 0.00% of their portfolio Liverpool, X0 20,16420.2k $7.2k $7.2k 0.00% Unchanged